113 related articles for article (PubMed ID: 32474729)
1. Immunohistochemical analysis of SLFN11 expression uncovers potential non-responders to DNA-damaging agents overlooked by tissue RNA-seq.
Takashima T; Sakamoto N; Murai J; Taniyama D; Honma R; Ukai S; Maruyama R; Kuraoka K; Rajapakse VN; Pommier Y; Yasui W
Virchows Arch; 2021 Mar; 478(3):569-579. PubMed ID: 32474729
[TBL] [Abstract][Full Text] [Related]
2. The emerging role of Schlafen-11 (SLFN11) in predicting response to anticancer treatments: Focus on small cell lung cancer.
Scattolin D; Maso AD; Ferro A; Frega S; Bonanno L; Guarneri V; Pasello G
Cancer Treat Rev; 2024 May; 128():102768. PubMed ID: 38797062
[TBL] [Abstract][Full Text] [Related]
3. Identification of Schlafen-11 as a Target of CD47 Signaling That Regulates Sensitivity to Ionizing Radiation and Topoisomerase Inhibitors.
Kaur S; Schwartz AL; Jordan DG; Soto-Pantoja DR; Kuo B; Elkahloun AG; Mathews Griner L; Thomas CJ; Ferrer M; Thomas A; Tang SW; Rajapakse VN; Pommier Y; Roberts DD
Front Oncol; 2019; 9():994. PubMed ID: 31632920
[TBL] [Abstract][Full Text] [Related]
4. Deconvolution of cell type-specific drug responses in human tumor tissue with single-cell RNA-seq.
Zhao W; Dovas A; Spinazzi EF; Levitin HM; Banu MA; Upadhyayula P; Sudhakar T; Marie T; Otten ML; Sisti MB; Bruce JN; Canoll P; Sims PA
Genome Med; 2021 May; 13(1):82. PubMed ID: 33975634
[TBL] [Abstract][Full Text] [Related]
5. Correlation of Systemic Inflammation Parameters and Serum SLFN11 in Small Cell Lung Cancer-A Prospective Pilot Study.
Simić I; Guzonjić A; Kotur Stevuljević J; Ćeriman Krstić V; Samardžić N; Savić Vujović K; Jovanović D
Biomedicines; 2024 Apr; 12(5):. PubMed ID: 38790938
[TBL] [Abstract][Full Text] [Related]
6. Schlafen 11 expression in human acute leukemia cells with gain-of-function mutations in the interferon-JAK signaling pathway.
Murai Y; Jo U; Murai J; Fukuda S; Takebe N; Pommier Y
iScience; 2021 Oct; 24(10):103173. PubMed ID: 34693224
[TBL] [Abstract][Full Text] [Related]
7. SLFN11 promotes stalled fork degradation that underlies the phenotype in Fanconi anemia cells.
Okamoto Y; Abe M; Mu A; Tempaku Y; Rogers CB; Mochizuki AL; Katsuki Y; Kanemaki MT; Takaori-Kondo A; Sobeck A; Bielinsky AK; Takata M
Blood; 2021 Jan; 137(3):336-348. PubMed ID: 32735670
[TBL] [Abstract][Full Text] [Related]
8. The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy.
Kagami T; Yamade M; Suzuki T; Uotani T; Tani S; Hamaya Y; Iwaizumi M; Osawa S; Sugimoto K; Miyajima H; Baba S; Sugimura H; Murai J; Pommier Y; Furuta T
BMC Cancer; 2020 Nov; 20(1):1123. PubMed ID: 33218331
[TBL] [Abstract][Full Text] [Related]
9. A case of Turcot's syndrome type 1 with loss of immunoexpression of MSH6 in colon cancer and liver metastasis due to secondary somatic mutation in coding mononucleotide (C)8 tract: a case report.
Akabane S; Hinoi T; Akagi K; Yamamoto H; Sada H; Shimizu Y; Shimizu W; Sudo T; Onoe T; Ishiyama K; Suzuki T; Tazawa H; Hadano N; Misumi T; Kojima M; Kubota H; Taniyama D; Kuraoka K; Tashiro H
BMC Med Genet; 2020 Jul; 21(1):141. PubMed ID: 32611331
[TBL] [Abstract][Full Text] [Related]
10. SLFN11 informs on standard of care and novel treatments in a wide range of cancer models.
Winkler C; Armenia J; Jones GN; Tobalina L; Sale MJ; Petreus T; Baird T; Serra V; Wang AT; Lau A; Garnett MJ; Jaaks P; Coker EA; Pierce AJ; O'Connor MJ; Leo E
Br J Cancer; 2021 Mar; 124(5):951-962. PubMed ID: 33339894
[TBL] [Abstract][Full Text] [Related]
11. Schlafen 11 predicts response to platinum-based chemotherapy in gastric cancers.
Takashima T; Taniyama D; Sakamoto N; Yasumoto M; Asai R; Hattori T; Honma R; Thang PQ; Ukai S; Maruyama R; Harada K; Kuraoka K; Tanabe K; Sasaki AT; Ohdan H; Morii E; Murai J; Yasui W
Br J Cancer; 2021 Jul; 125(1):65-77. PubMed ID: 33785877
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic suppression of SLFN11 in germinal center B-cells during B-cell development.
Moribe F; Nishikori M; Takashima T; Taniyama D; Onishi N; Arima H; Sasanuma H; Akagawa R; Elloumi F; Takeda S; Pommier Y; Morii E; Takaori-Kondo A; Murai J
PLoS One; 2021; 16(1):e0237554. PubMed ID: 33513156
[TBL] [Abstract][Full Text] [Related]
13. The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response.
Coleman N; Zhang B; Byers LA; Yap TA
Br J Cancer; 2021 Mar; 124(5):857-859. PubMed ID: 33328609
[TBL] [Abstract][Full Text] [Related]
14. SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors.
Jo U; Murai Y; Chakka S; Chen L; Cheng K; Murai J; Saha LK; Miller Jenkins LM; Pommier Y
Proc Natl Acad Sci U S A; 2021 Feb; 118(6):. PubMed ID: 33536335
[TBL] [Abstract][Full Text] [Related]
15. Sustained remission of multi-line relapsed extranodal NK/T-cell lymphoma, nasal type, following sintilimab and chidamide: A case report.
Xu J; Xu X; Chen J; Wang J; Jiang C; Lv C; Chen B
Medicine (Baltimore); 2021 Mar; 100(10):e24824. PubMed ID: 33725836
[TBL] [Abstract][Full Text] [Related]
16. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14).
Gillessen S; Plütschow A; Fuchs M; Markova J; Greil R; Topp MS; Meissner J; Zijlstra JM; Eichenauer DA; Bröckelmann PJ; Diehl V; Borchmann P; Engert A; von Tresckow B
Lancet Haematol; 2021 Apr; 8(4):e278-e288. PubMed ID: 33770483
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemoradiotherapy improves survival in locally advanced adenocarcinoma of esophagogastric junction compared with neoadjuvant chemotherapy: a propensity score matching analysis.
Li J; Zhao Q; Ge X; Song Y; Tian Y; Wang S; Liu M; Qiao X
BMC Surg; 2021 Mar; 21(1):137. PubMed ID: 33731072
[TBL] [Abstract][Full Text] [Related]
18. Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer.
Fernandez-Martinez A; Krop IE; Hillman DW; Polley MY; Parker JS; Huebner L; Hoadley KA; Shepherd J; Tolaney S; Henry NL; Dang C; Harris L; Berry D; Hahn O; Hudis C; Winer E; Partridge A; Perou CM; Carey LA
J Clin Oncol; 2020 Dec; 38(35):4184-4193. PubMed ID: 33095682
[TBL] [Abstract][Full Text] [Related]
19. Genomic, Transcriptomic, and Functional Alterations in DNA Damage Response Pathways as Putative Biomarkers of Chemotherapy Response in Ovarian Cancer.
Sharma Saha S; Gentles L; Bradbury A; Brecht D; Robinson R; O'Donnell R; Curtin NJ; Drew Y
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33804647
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
